ClinicalTrials.gg
CompletedNCT01316913Updated Apr 4, 2017Results posted

24-week Trial Comparing GSK573719/GW642444 With GSK573719 and With Tiotropium in Chronic Obstructive Pulmonary Disease

A Phase 3 interventional study of GSK573719/GW642444 125/25 and GSK573719/GW642444 62.5/25 in Pulmonary Disease, Chronic Obstructive, sponsored by GlaxoSmithKline. Completed at 100 sites in 10 countries. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2017-04-04.

Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
872
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 43 studies testing GSK573719 in Pulmonary Disease, Chronic Obstructive — 3 open to participants now, 3 under way, none of them phase 3. GSK573719 · Pulmonary Disease, Chronic Obstructive.

Enrollment
6th of 43
872 · median 131
Started
2011
with 7 others
Phase 3
14 of 43
none open now
Registered
9th of 43
by date
Lead sponsor
35 of 43
GlaxoSmithKline

Among the 43 studies testing GSK573719 in Pulmonary Disease, Chronic Obstructive, this one is the 6th largest by enrollment, is one of 8 that started in 2011, is one of 14 in phase 3, and was the 9th registered.

Pulmonary Disease, Chronic Obstructive

5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 857 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

3 of the 43 studies testing GSK573719 in Pulmonary Disease, Chronic Obstructive are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About GSK573719

GSK573719: first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 557 Pulmonary Disease, Chronic Obstructive studies recruiting now, 306 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 89 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies testing GSK573719 in Pulmonary Disease, Chronic Obstructive, or all of them as a file.
02

Study summary

This is a Phase III multicenter, randomized, double-blind, double-dummy, parallel-group study to evaluate the efficacy and safety of two doses of GSK573719/GW642444 Inhalation Powder, GSK573719 Inhalation Powder via a Novel Dry Powder Inhaler and tiotropium via HandiHaler when administered once-daily over a 24-week treatment period in subjects with chronic obstructive pulmonary disease (COPD). Subjects who meet eligibility criteria at Screening (Visit 1) will complete a 7 to10 day run-in period followed by a randomization visit (Visit 2) then a 24-week treatment period. There will be a total of 9 clinic study visits. A follow-up phone contact for adverse event assessment will be conducted approximately one week after the last study visit (Visit 9 or Early Withdrawal). The total duration of subject participation in the study will be approximately 26 weeks. The primary measure of efficacy is clinic visit trough (pre-bronchodilator and pre-dose) forced expiratory volume in one second (FEV1) on Treatment Day 169. Safety will be assessed by adverse events, 12-lead ECGs, vital signs, and clinical laboratory tests.

Read the detailed description

This is a 24-week, Phase III multicenter, randomized, double-blind, double-dummy, parallel-group study. Eligible subjects will be randomized to GSK573719/GW642444 125/25mcg, GSK573719/GW642444 62.5/25mcg, GSK573719 125mcg, or tiotropium treatment groups in a 1:1:1:1 ratio. Treatments will be administered once-daily in the morning by inhalation using a Novel Dry Powder Inhaler (Novel DPI) and HandiHaler. There will be a total of 9 study clinic visits conducted on an outpatient basis. Subjects who meet the eligibility criteria at Screening (Visit 1) will complete a 7 to 10 day run-in period followed by a 24-week treatment period. Clinic visits will be at Screening, Randomization (Day 1), Day 2, after 4, 8, 12, 16, and 24-weeks of treatment, and 1 day after the Week 24 Visit (also referred as Treatment Day 169). A follow-up contact for adverse assessment will be conducted by telephone approximately 7 days after Visit 9 or the Early Withdrawal Visit. The total duration of subject participation, including follow-up will be approximately 26 weeks. All subjects will be provided with albuterol/salbutamol for use on an "as-needed" basis throughout the run-in and study treatment periods. At screening, pre-bronchodilator spirometry testing will be followed by post-albuterol/salbutamol spirometry testing. Post-albuterol/salbutamol FEV1 and FEV1/forced vital capacity (FVC) values will be used to determine subject eligibility. To further characterize bronchodilator responsiveness, post-ipratropium testing will be conducted following completion of post-albuterol/salbutamol spirometry. Spirometry will be conducted at each post-randomization clinic visit. Six hour post-dose serial spirometry will be conducted at Visits 2, 6, and 8. Trough spirometry will be obtained 23 and 24 hours after the previous day's dose of blinded study medication at Visits 3 to 9. All subjects will be provided with an electronic diary (eDiary) for completion daily in the morning and the evening throughout the run-in and treatment periods. Subjects will use the eDiary to record peak expiratory flow (PEF) each morning, dyspnea scores using the Shortness of Breath with Daily Activities instrument (SOBDA), daily use of supplemental albuterol/salbutamol as either puffs/day from a metered-dose inhaler (MDI) and/or nebules used per day, and any healthcare contacts related to COPD. Additional assessments of dyspnea will be obtained using the Baseline and Transition Dyspnea Index (BDI/TDI) which is an interviewer based instrument. At Visit 2, the severity of dyspnea at baseline will be assessed using the BDI. At subsequent visits (Visits 4, 6, and 8) change from baseline will be assessed using the TDI. General health status will be evaluated using the subject-completed EQ-5D questionnaire at Visits 2, 4, 6, and 8. Disease specific health status will be evaluated using the subject-completed St. George's Respiratory Questionnaire (SGRQ) at Visits 2, 4, 6, and 8, and the subject-completed COPD Assessment Test (CAT) at Visits 2, 6, and 8. The occurrence of adverse events will be evaluated throughout the study beginning at Visit 2. SAEs will be collected over the same time period as for AEs. However, any SAEs assessed as related to study participation (e.g., study treatment, protocol-mandated procedures, invasive tests, or change in existing therapy) or related to a GSK concomitant medication, will be recorded from the time a subject consents to participate in the study up to and including any follow up contact. Additional safety assessments of vital signs (blood pressure and pulse rate), 12-lead ECGs and standard clinical laboratory tests (hematology and chemistry) will be obtained at selected clinic visits.

03

Conditions studied

  • Pulmonary Disease, Chronic Obstructive

Keywords

  • tiotropium
  • long-acting muscarinic antagonist
  • COPD
  • long-acting beta agonist
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • outpatient
  • signed and dated written
  • 40 years of age or older
  • male and female subjects
  • diagnosis
  • at least 10 pack-year smoking history
  • post-albuterol/salbutamol /FVC ratio of \<0.70 and post-albuterol/salbutamol FEV1 of less than or equal to 70% predicted normal values
  • score of greater than or equal to 2 on the Modified Medical Resarch Council Dyspnea Scale (mMRC)

Exclusion criteria

Exclusion Criteria:

  • women who are pregnant or lactating or are planning on becoming pregnant during the study
  • current diagnosis of asthma
  • other respiratory disorders other than
  • other diseases/abnormalities that are uncontrolled including cancer not in remission for at least 5 years
  • chest x-ray or CT scan with abnormalities not believed to be due to COPD
  • to anticholinergics, beta-agonists, lactose/milk protein or magnesium stearate or medical conditions associated with inhaled anticholinergics
  • hospitalization for COPD or pneumonia within 12 weeks prior to Visit 1
  • lung volume reduction surgery within 12 months prior to Visit 1
  • abnormal and clinically significant at Visit 1
  • significantly abnormal finding from laboratory tests at Visit 1
  • unable to withhold albuterol/salbutamol at least 4 hours prior to spirometry at each visit
  • use of depot within 12 weeks of Visit 1
  • use of oral or parenteral corticosteroids, antibiotics for lower respiratory tract infection, or cytochrome P450 3A4 inhibitors, within 6 weeks of Visit 1
  • use of long-acting beta-agonist (LABA)/inhaled corticosteroid (ICS) product if LABA/ICS therapy is discontinued withing 30 days of Visit 1
  • use of ICS at a dose of >1000mcg/day of fluticasone propionate or equivalent within 30 days of Visit 1
  • initiation or discontinuation of ICS within 30 days of Visit 1
  • use of tiotropium or roflumilast within 14 days of Visit 1
  • use of theophyllines, oral leukotriene inhibitors, long-acting oral beta-agonists, or inhaled long-acting beta-agonists within 48 hours of Visit 1
  • short-acting oral beta-agonists within 12 hours of Visit 1
  • use of LABA/ICS combination products only if discontinuing LABA therapy and switching to ICS monotherapy within 48 hours of Visit 1 for the LABA component
  • use of sodium cromoglycate or nedocromil sodium within 24 hours of Visit 1
  • use of inhaled short-acting beta-agonists, inhaled short-acting anticholinergics, or inhaled short-acting anticholinergic/short-acting beta-agonist combination products within 4 hours of Visit 1
  • use of any other medication within 30 days or 5 drug half-lives (whichever is longer)
  • long-term oxygen therapy prescribed for >12 hours per day
  • regular use of nebulized short-acting bronchodilators
  • participation in acute phase of pulmonary rehabilitation program
  • known or suspected history of alcohol or drug abse within 2 years prior to Visit 1
  • anyone affiliated with the investigator site (e.g., investigator, sub-investigator, study coordinator, employee of a participating investigator or study site, or immediate family member)
  • previous exposure to GSK573719, GSK573719/GW642444 combination, GW642444 (vilanterol), or fluticasone furoate/GW642444 combination
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
872 participants (actual)

Study arms

  • Experimental
    GSK573719/GW642444 125/25

    125/25 mcg once-daily

    Drug: GSK573719/GW642444 125/25

  • Experimental
    GSK573719/GW642444 62.5/25

    62.5/25 mcg once-daily

    Drug: GSK573719/GW642444 62.5/25

  • Experimental
    GSK573719

    125 mcg once-daily

    Drug: GSK573719

  • Active comparator
    tiotropium bromide

    18 mcg once-daily

    Drug: tiotropium bromide

Interventions

  • DrugGSK573719/GW642444 125/25

    125/25 mcg once-daily

    Also known as: GSK573719/vilanterol trifenatate

  • DrugGSK573719/GW642444 62.5/25

    62.5/25 mcg once-daily

    Also known as: GSK573719/vilanterol trifenatate

  • 125 mcg once-daily

  • 18 mcg once-daily

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Clinic Visit Trough Forced Expiratory Volume in One Second (FEV1) at Day 169

    FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. Trough FEV1 measurements were taken electronically by spirometry on Days 2, 28, 56, 84, 112, 168, and 169. Baseline is defined as the mean of the assessments made 30 minutes pre-dose and 5 minutes pre-dose on Treatment Day 1. Trough FEV1 is defined as the mean of the FEV1 values obtained at 23 and 24 hours after the previous morning's dosing (i.e., trough FEV1 on Day 169 is the mean of the FEV1 values obtained 23 and 24 hours after the morning dosing on Day 168). Change from Baseline at a particular visit was calculated as the trough FEV1 at that visit minus Baseline. Analysis was performed using a repeated measures model with covariates of treatment, Baseline, smoking status, center group, day, and day by Baseline and day by treatment interactions. ITT=Intent-to-Treat.

    Time frame: Baseline and Day 169

Secondary outcomes

  1. Change From Baseline (BL) in Weighted Mean (WM) 0-6 Hour FEV1 Obtained Post-dose at Day 168

    FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. The WM FEV1 was derived by calculating the area under the FEV1/time curve (AUC) using the trapezoidal rule, and then dividing the value by the time interval over which the AUC was calculated. The WM was calculated at Days 1, 84, and Day 168 using the 0-6-hour post-dose FEV1 measurements collected on that day, which included pre-dose (Day 1: 30 minutes \[min\] and 5 min prior to dosing; other serial visits: 23 and 24 hours after the previous morning dose) and post-dose at 15 minutes, 30 minutes, 1 hour, 3 hours, and 6 hours. Change from BL at a particular visit was calculated as WM at that visit minus BL. Analysis was performed using a repeated measures model with covariates of treatment, BL (mean of the two assessments made 30 minutes and 5 minutes pre-dose on Day 1), smoking status, center group, day, and day by BL and day by treatment interactions.

    Time frame: Baseline and Day 168

Other outcomes

  1. Change From Baseline (BL) in the Mean Shortness of Breath With Daily Activities (SOBDA) Score for Week 24

    The newly developed SOBDA questionnaire assesses dyspnea or shortness of breath (SOB) with daily activities. The SOBDA questionnaire is made up of 13 items completed by the participant (par.) each evening prior to bedtime, when the par. is instructed to reflect on the current day's activities. The daily score is computed as the mean of the scores on the 13 items (\>=7 items must have non-missing responses for this to be calculated). The par. is assigned a weekly mean SOBDA score ranging from 1 to 4 (greater scores indicate more severe breathlessness with daily activities) based on the mean of 7 days of data (\>=4 of 7 days must be completed for a weekly mean to be calculated). Change from BL is the mean weekly SOBDA score minus BL. Analysis was performed using MMRM with covariates of treatment, BL (mean score in the week prior to treatment), smoking status, center group, week, week by BL and week by treatment interactions. This MMRM analysis only included Weeks 4, 8, 12, and 24.

    Time frame: Baseline and Week 24

07

Results

Posted Feb 24, 2014

Participant flow

Participant flow — Overall Study
MilestoneUMEC 125 µg QDUMEC/VI 62.5/25 µg QDUMEC/VI 125/25 µg QDTIO18 µg QD
Started222217215215
Completed165163166176
Not completed57544939
Withdrew: Adverse event17201511
Withdrew: Lack of efficacy2212913
Withdrew: Protocol violation1441
Withdrew: Protocol-defined stopping criteria78116
Withdrew: Lost to follow-up0102
Withdrew: Withdrawal by subject109106

Outcome measures

PrimaryChange From Baseline in Clinic Visit Trough Forced Expiratory Volume in One Second (FEV1) at Day 169

FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. Trough FEV1 measurements were taken electronically by spirometry on Days 2, 28, 56, 84, 112, 168, and 169. Baseline is defined as the mean of the assessments made 30 minutes pre-dose and 5 minutes pre-dose on Treatment Day 1. Trough FEV1 is defined as the mean of the FEV1 values obtained at 23 and 24 hours after the previous morning's dosing (i.e., trough FEV1 on Day 169 is the mean of the FEV1 values obtained 23 and 24 hours after the morning dosing on Day 168). Change from Baseline at a particular visit was calculated as the trough FEV1 at that visit minus Baseline. Analysis was performed using a repeated measures model with covariates of treatment, Baseline, smoking status, center group, day, and day by Baseline and day by treatment interactions. ITT=Intent-to-Treat.

Time frame:
Baseline and Day 169
Reported as:
Least squares mean · Liters
Change From Baseline in Clinic Visit Trough Forced Expiratory Volume in One Second (FEV1) at Day 169
LitersUMEC 125 µg QDUMEC/VI 62.5/25 µg QDUMEC/VI 125/25 QDTIO18 µg QD
Change From Baseline in Clinic Visit Trough Forced Expiratory Volume in One Second (FEV1) at Day 1690.186 ± 0.01780.208 ± 0.01800.223 ± 0.01790.149 ± 0.0176
Statistical analysis
  • UMEC 125 µg QD vs UMEC/VI 62.5/25 µg QD · Mixed Models Analysis · p = 0.377 · Least squares mean difference: 0.022 · 95% CI -0.027 to 0.072Least squares mean difference=UMEC/VI 62.5/25 µg minus UMEC 125 µg.
  • UMEC/VI 62.5/25 µg QD vs TIO18 µg QD · Mixed Models Analysis · p = 0.018 (nominal p-value) · Least squares mean difference: 0.060 · 95% CI 0.010 to 0.109Least squares mean difference=UMEC/VI 62.5/25 µg minus TIO 18 µg.
  • UMEC 125 µg QD vs UMEC/VI 125/25 QD · Mixed Models Analysis · p = 0.142 · Least squares mean difference: 0.037 · 95% CI -0.012 to 0.087Least squares mean difference=UMEC/VI 125/25 µg minus UMEC 125 µg.
  • UMEC/VI 125/25 QD vs TIO18 µg QD · Mixed Models Analysis · p = 0.003 · Least squares mean difference: 0.074 · 95% CI 0.025 to 0.123Least squares mean difference=UMEC/VI 125/25 µg minus TIO 18 µg.
SecondaryChange From Baseline (BL) in Weighted Mean (WM) 0-6 Hour FEV1 Obtained Post-dose at Day 168

FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. The WM FEV1 was derived by calculating the area under the FEV1/time curve (AUC) using the trapezoidal rule, and then dividing the value by the time interval over which the AUC was calculated. The WM was calculated at Days 1, 84, and Day 168 using the 0-6-hour post-dose FEV1 measurements collected on that day, which included pre-dose (Day 1: 30 minutes \[min\] and 5 min prior to dosing; other serial visits: 23 and 24 hours after the previous morning dose) and post-dose at 15 minutes, 30 minutes, 1 hour, 3 hours, and 6 hours. Change from BL at a particular visit was calculated as WM at that visit minus BL. Analysis was performed using a repeated measures model with covariates of treatment, BL (mean of the two assessments made 30 minutes and 5 minutes pre-dose on Day 1), smoking status, center group, day, and day by BL and day by treatment interactions.

Time frame:
Baseline and Day 168
Reported as:
Least squares mean · Liters
Change From Baseline (BL) in Weighted Mean (WM) 0-6 Hour FEV1 Obtained Post-dose at Day 168
LitersUMEC 125 µg QDUMEC/VI 62.5/25 µg QDUMEC/VI 125/25 µg QDTIO18 µg QD
Change From Baseline (BL) in Weighted Mean (WM) 0-6 Hour FEV1 Obtained Post-dose at Day 1680.206 ± 0.01670.276 ± 0.01680.282 ± 0.01670.180 ± 0.0165
Other pre-specifiedChange From Baseline (BL) in the Mean Shortness of Breath With Daily Activities (SOBDA) Score for Week 24

The newly developed SOBDA questionnaire assesses dyspnea or shortness of breath (SOB) with daily activities. The SOBDA questionnaire is made up of 13 items completed by the participant (par.) each evening prior to bedtime, when the par. is instructed to reflect on the current day's activities. The daily score is computed as the mean of the scores on the 13 items (\>=7 items must have non-missing responses for this to be calculated). The par. is assigned a weekly mean SOBDA score ranging from 1 to 4 (greater scores indicate more severe breathlessness with daily activities) based on the mean of 7 days of data (\>=4 of 7 days must be completed for a weekly mean to be calculated). Change from BL is the mean weekly SOBDA score minus BL. Analysis was performed using MMRM with covariates of treatment, BL (mean score in the week prior to treatment), smoking status, center group, week, week by BL and week by treatment interactions. This MMRM analysis only included Weeks 4, 8, 12, and 24.

Time frame:
Baseline and Week 24
Reported as:
Least squares mean · scores on a scale
Change From Baseline (BL) in the Mean Shortness of Breath With Daily Activities (SOBDA) Score for Week 24
scores on a scaleUMEC 125 µg QDUMEC/VI 62.5/25 µg QDUMEC/VI 125/25 µg QDTIO18 µg QD
Change From Baseline (BL) in the Mean Shortness of Breath With Daily Activities (SOBDA) Score for Week 24-0.19 ± 0.041-0.29 ± 0.040-0.33 ± 0.040-0.21 ± 0.040

Adverse events

Collected over On-treatment serious adverse events (SAEs) and non-serious adverse events (AEs) were collected from the start of study medication until the end of treatment (up to 24 weeks).. Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
UMEC 125 µg QD—15/222 (6.8%)75/222 (33.8%)
UMEC/VI 62.5/25 µg QD—22/217 (10.1%)63/217 (29%)
UMEC/VI 125/25 µg QD—15/215 (7%)66/215 (30.7%)
TIO18 µg QD—9/215 (4.2%)62/215 (28.8%)
Most frequent serious events
Showing 10 of 50
Most frequent serious events
EventUMEC 125 µg QDUMEC/VI 62.5/25 µg QDUMEC/VI 125/25 µg QDTIO18 µg QD
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders2/2227/2176/2151/215
PneumoniaInfections and infestations2/2222/2173/2152/215
Coronary artery diseaseCardiac disorders0/2220/2172/2150/215
Infective exacerbation of chronic obstructive airways diseasInfections and infestations0/2222/2170/2150/215
Herpes zosterInfections and infestations0/2220/2171/2150/215
InfluenzaInfections and infestations0/2220/2170/2151/215
Soft tissue infectionInfections and infestations0/2220/2171/2150/215
PneumothoraxRespiratory, thoracic and mediastinal disorders0/2220/2171/2150/215
Respiratory arrestRespiratory, thoracic and mediastinal disorders0/2220/2170/2151/215
Facial bones fractureInjury, poisoning and procedural complications0/2220/2171/2150/215
Most frequent other events
Most frequent other events
EventUMEC 125 µg QDUMEC/VI 62.5/25 µg QDUMEC/VI 125/25 µg QDTIO18 µg QD
HeadacheNervous system disorders25/22221/21720/21515/215
NasopharyngitisInfections and infestations6/22214/21716/21517/215
Upper respiratory tract infectionInfections and infestations17/2226/21710/21514/215
CoughRespiratory, thoracic and mediastinal disorders14/2225/2178/2156/215
Back painMusculoskeletal and connective tissue disorders10/2228/2176/21511/215
HypertensionVascular disorders9/2221/2174/2157/215
Lower respiratory tract infectionInfections and infestations1/2228/2173/2152/215
Oropharyngeal painRespiratory, thoracic and mediastinal disorders8/2223/2176/2153/215
DiarrhoeaGastrointestinal disorders8/2224/2171/2155/215
Pain in extremityMusculoskeletal and connective tissue disorders1/2227/2176/2154/215

Baseline characteristics

Age, Continuous
Age, Continuous(Years)UMEC 125 µg QDUMEC/VI 62.5/25 µg QDUMEC/VI 125/25 µg QDTIO18 µg QDTotal
Mean64.5 ± 8.3365.0 ± 8.6263.8 ± 8.5165.2 ± 8.3064.6 ± 8.44
Sex: Female, Male
Sex: Female, Male(Participants)UMEC 125 µg QDUMEC/VI 62.5/25 µg QDUMEC/VI 125/25 µg QDTIO18 µg QDTotal
Female74776762280
Male148140148153589
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)UMEC 125 µg QDUMEC/VI 62.5/25 µg QDUMEC/VI 125/25 µg QDTIO18 µg QDTotal
African American/African Heritage689831
Asian - East Asian Heritage35343634139
Asian - South East Asian Heritage21126
Native Hawaiian or other Pacific Islander01001
White - Arabic/North African Heritage10001
White - White/Caucasian/European Heritage169163160163655
White - Mixed Race01001
Mixed Race999835
08

Study locations

100 sites
  • GSK Investigational Site
    Jasper, Alabama 35501, United States
  • GSK Investigational Site
    Mobile, Alabama 36608, United States
  • GSK Investigational Site
    Huntington Beach, California 92647, United States
  • GSK Investigational Site
    Los Angeles, California 90048, United States
  • GSK Investigational Site
    Clearwater, Florida 33765, United States
  • GSK Investigational Site
    Ormond Beach, Florida 32174, United States
  • GSK Investigational Site
    Lawrenceville, Georgia 30046, United States
  • GSK Investigational Site
    Topeka, Kansas 66606, United States
  • GSK Investigational Site
    Madisonville, Kentucky 42431, United States
  • GSK Investigational Site
    Lafayette, Louisiana 70503, United States
  • GSK Investigational Site
    New Orleans, Louisiana 70115, United States
  • GSK Investigational Site
    St. Louis, Missouri 63141, United States
  • GSK Investigational Site
    Charlotte, North Carolina 28207, United States
  • GSK Investigational Site
    Elizabeth City, North Carolina 27909, United States
  • GSK Investigational Site
    Cincinnati, Ohio 45231, United States
  • GSK Investigational Site
    Medford, Oregon 97504, United States
  • GSK Investigational Site
    Beaver, Pennsylvania 15009, United States
  • GSK Investigational Site
    Easley, South Carolina 29640, United States
  • GSK Investigational Site
    Spartanburg, South Carolina 29303, United States
  • GSK Investigational Site
    Morgantown, West Virginia 26505, United States
  • GSK Investigational Site
    Ciudad Autonoma de Buenos Aires, Buenos Aires C1028AAP, Argentina
  • GSK Investigational Site
    Buenos Aires, C1424BSF, Argentina
  • GSK Investigational Site
    Buenos Aires, C1425BEN, Argentina
  • GSK Investigational Site
    Ciudad Autónoma de Buenos Aires, C1426ABP, Argentina
  • GSK Investigational Site
    Mendoza, M5500CCG, Argentina
  • GSK Investigational Site
    Concord, New South Wales 2139, Australia
  • GSK Investigational Site
    Cairns, Queensland 4870, Australia
  • GSK Investigational Site
    Carina Heights, Queensland 4152, Australia
  • GSK Investigational Site
    Kippa Ring, Queensland 4021, Australia
  • GSK Investigational Site
    Adelaide, South Australia 5000, Australia
  • GSK Investigational Site
    Daw Park, South Australia 5041, Australia
  • GSK Investigational Site
    Frankston, Victoria 3199, Australia
  • GSK Investigational Site
    Parkville, Victoria 3050, Australia
  • GSK Investigational Site
    Nedlands, Western Australia 6009, Australia
  • GSK Investigational Site
    Winnipeg, Manitoba R2H 2A6, Canada
  • GSK Investigational Site
    Winnipeg, Manitoba R2K 3S8, Canada
  • GSK Investigational Site
    Bay Roberts, Newfoundland and Labrador A0A 1G0, Canada
  • GSK Investigational Site
    Truro, Nova Scotia B2N 1L2, Canada
  • GSK Investigational Site
    Mississauga, Ontario L5M 2V8, Canada
  • GSK Investigational Site
    Sudbury, Ontario P3E 1H5, Canada
  • GSK Investigational Site
    Toronto, Ontario M5T 3A9, Canada
  • GSK Investigational Site
    Gatineau, Quebec J8Y 6S8, Canada
  • GSK Investigational Site
    St-Romulad, Quebec G6W 5M6, Canada
  • GSK Investigational Site
    Quebec, G1V 4G5, Canada
  • GSK Investigational Site
    Puerto Montt, Región De Los Lagos 5480000, Chile
  • GSK Investigational Site
    Santiago, Región Metro De Santiago 7500551, Chile
  • GSK Investigational Site
    Santiago, Región Metro De Santiago 7500710, Chile
  • GSK Investigational Site
    Santiago, Región Metro De Santiago 7500800, Chile
  • GSK Investigational Site
    Santiago, Región Metro De Santiago 7601003, Chile
  • GSK Investigational Site
    Talca, Región Metro De Santiago 3460001, Chile
  • GSK Investigational Site
    Santiago, 8380453, Chile
  • GSK Investigational Site
    Schwetzingen, Baden-Wuerttemberg 68723, Germany
  • GSK Investigational Site
    Aschaffenburg, Bayern 63739, Germany
  • GSK Investigational Site
    Oranienburg, Brandenburg 16515, Germany
  • GSK Investigational Site
    Ruedersdorf, Brandenburg 15562, Germany
  • GSK Investigational Site
    Schwedt, Brandenburg 16303, Germany
  • GSK Investigational Site
    Frankfurt, Hessen 60389, Germany
  • GSK Investigational Site
    Kassel, Hessen 34121, Germany
  • GSK Investigational Site
    Wolfenbuettel, Niedersachsen 38300, Germany
  • GSK Investigational Site
    Dueren, Nordrhein-Westfalen 52349, Germany
  • GSK Investigational Site
    Essen, Nordrhein-Westfalen 45355, Germany
  • GSK Investigational Site
    Essen, Nordrhein-Westfalen 45359, Germany
  • GSK Investigational Site
    Koblenz, Rheinland-Pfalz 56068, Germany
  • GSK Investigational Site
    Mainz, Rheinland-Pfalz 55116, Germany
  • GSK Investigational Site
    Leipzig, Sachsen 04207, Germany
  • GSK Investigational Site
    Berlin, 10629, Germany
  • GSK Investigational Site
    Berlin, 12099, Germany
  • GSK Investigational Site
    Hamburg, 22335, Germany
  • GSK Investigational Site
    Bucheon-si,, 420-767, Korea, Republic of
  • GSK Investigational Site
    Cheongju, Chungcheongbuk-do, 361-711, Korea, Republic of
  • GSK Investigational Site
    Daegu, 705-717, Korea, Republic of
  • GSK Investigational Site
    Incheon, 400-711, Korea, Republic of
  • GSK Investigational Site
    Incheon, 405-760, Korea, Republic of
  • GSK Investigational Site
    Kangwon-do, 220-701, Korea, Republic of
  • GSK Investigational Site
    Seongnam-si, Gyeonggi-do, 463-707, Korea, Republic of
  • GSK Investigational Site
    Seoul, 100-032, Korea, Republic of
  • GSK Investigational Site
    Seoul, 110-744, Korea, Republic of
  • GSK Investigational Site
    Seoul, 130-702, Korea, Republic of
  • GSK Investigational Site
    Seoul, 130-848, Korea, Republic of
  • GSK Investigational Site
    Seoul, 136-705, Korea, Republic of
  • GSK Investigational Site
    Seoul, 143-729, Korea, Republic of
  • GSK Investigational Site
    Seoul, 152-703, Korea, Republic of
  • GSK Investigational Site
    Seoul, 156-707, Korea, Republic of
  • GSK Investigational Site
    Seoul, Korea, Republic of
  • GSK Investigational Site
    Suwon, Kyonggi-do, 443-721, Korea, Republic of
  • GSK Investigational Site
    Zapopan, Jalisco 45040, Mexico
  • GSK Investigational Site
    Monterrey, Nuevo León 64020, Mexico
  • GSK Investigational Site
    Durango, 34080, Mexico
  • GSK Investigational Site
    Mexico, 14000, Mexico
  • GSK Investigational Site
    Constanta, 900002, Romania
  • GSK Investigational Site
    Ploiesti, 100379, Romania
  • GSK Investigational Site
    Targoviste, 130086, Romania
  • GSK Investigational Site
    Bloemfontein, 9301, South Africa
  • GSK Investigational Site
    Boksburg North, 1459, South Africa
  • GSK Investigational Site
    Die Wilgers, 0041, South Africa
  • GSK Investigational Site
    Durban, 4091, South Africa
  • GSK Investigational Site
    Gatesville, 7764, South Africa
  • GSK Investigational Site
    Groenkloof, 0181, South Africa
  • GSK Investigational Site
    Pretoria, 0002, South Africa
  • GSK Investigational Site
    Thabazimbi, 0380, South Africa
09

References and documents

Publications

  • Maleki-Yazdi MR, Singh D, Anzueto A, Tombs L, Fahy WA, Naya I. Assessing Short-term Deterioration in Maintenance-naive Patients with COPD Receiving Umeclidinium/Vilanterol and Tiotropium: A Pooled Analysis of Three Randomized Trials. Adv Ther. 2017 Jan;33(12):2188-2199. doi: 10.1007/s12325-016-0430-6. Epub 2016 Oct 28. PubMed 27796912 ↗
  • Decramer M, Anzueto A, Kerwin E, Kaelin T, Richard N, Crater G, Tabberer M, Harris S, Church A. Efficacy and safety of umeclidinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in patients with chronic obstructive pulmonary disease: results from two multicentre, blinded, randomised controlled trials. Lancet Respir Med. 2014 Jun;2(6):472-86. doi: 10.1016/S2213-2600(14)70065-7. Epub 2014 May 14. PubMed 24835833 ↗

Individual participant data

Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2011, a primary completion of Apr 2012 and a completion of Apr 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2014, 1 year 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 15, 2011
First posted
Mar 16, 2011
Start
Mar 2011
Primary completionActual
Apr 2012
CompletionActual
Apr 2012
Results first posted
Feb 24, 2014
Last update
Apr 4, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 4, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01316913
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Mar 16, 2011
Start date
Mar 2011
Primary completion
Apr 2012
Completion
Apr 2012
Results posted
Feb 24, 2014
Last update
Apr 4, 2017

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: GSK573719

Start the discussion